BioSpace News Archive

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update.

AKL Research and Development, a pharmaceutical company which develops novel solutions for inflammatory diseases with a high unmet need, unveils new data at the Osteoarthritis Research Society International Virtual World Congress indicating its investigational oral osteoarthritis drug APPA can modulate cellular function, reduce inflammation and inhibit bone resorption associated with joint degradation caused by the disease.

MESI mTABLET ABI, device used for early detection of Peripheral Arterial Disease by measuring Ankle-Brachial Index, has been announced as a finalist in the Cardiovascular Device category in the 2021 Medical Design Awards competition.

Core One Labs Inc.,, a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has entered into a definitive share purchase agreement, dated April 23, 2021, pursuant to which it will acquire all of the outstanding share capital of Akome Biotech Ltd.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of the stroke caused by carotid artery disease, announces the formation of its Scientific Advisory Board with its newly appointed chair, acclaimed interventional cardiologist, Kenneth Rosenfield, M.D.

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced that it will host a conference call to discuss its first quarter 2021 financial results on Monday, May 10th, 2021 at 7:30 a.m. Pacific Time.

West Pharmaceutical Services, Inc. announced its financial results for the first-quarter 2021 and updated full-year 2021 financial guidance.

Lucira Health, Inc., a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, announced the opening of a new production center in the Dominican Republic by its manufacturing partner Jabil Inc.

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2021.

Highlights Revenue of $1,208.7 million for the three months ended March 31, 2021, representing a sequential increase of 6.0% compared to the three months ended December 31, 2020, and a year-over-year increase of 3.9% compared to the three months ended March 31, 2020. Net new business awards of $1,548.8 million and $5,880.1 million for the three and twelve months ended March 31, 2021, representing book-to-bill ratios of 1.28x and 1.32x, respectively.